A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of OVID stock, worth $4,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,900
Previous 2,200 168.18%
Holding current value
$4,543
Previous $7,000 142.86%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.72 - $4.04 $370,292 - $549,993
136,137 Added 1215.29%
147,339 $449,000
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $33,381 - $42,343
11,202 New
11,202 $36,000
Q2 2023

Aug 14, 2023

SELL
$2.53 - $3.89 $68,373 - $105,127
-27,025 Reduced 46.73%
30,812 $101,000
Q1 2023

May 15, 2023

BUY
$1.88 - $2.85 $37,240 - $56,455
19,809 Added 52.09%
57,837 $149,000
Q4 2022

Feb 14, 2023

BUY
$1.43 - $1.86 $54,380 - $70,732
38,028 New
38,028 $70,000
Q1 2022

May 16, 2022

SELL
$2.65 - $3.49 $106,424 - $140,158
-40,160 Reduced 51.21%
38,265 $120,000
Q4 2021

Feb 14, 2022

SELL
$3.13 - $3.73 $58,214 - $69,374
-18,599 Reduced 19.17%
78,425 $251,000
Q3 2021

Nov 15, 2021

BUY
$3.31 - $4.04 $201,615 - $246,080
60,911 Added 168.67%
97,024 $326,000
Q2 2021

Aug 16, 2021

SELL
$3.3 - $4.49 $150,661 - $204,990
-45,655 Reduced 55.83%
36,113 $141,000
Q1 2021

May 17, 2021

BUY
$2.42 - $4.47 $9,590 - $17,714
3,963 Added 5.09%
81,768 $329,000
Q4 2020

Feb 16, 2021

SELL
$2.28 - $6.84 $52,451 - $157,354
-23,005 Reduced 22.82%
77,805 $180,000
Q3 2020

Nov 16, 2020

BUY
$5.39 - $8.24 $424,354 - $648,735
78,730 Added 356.57%
100,810 $579,000
Q2 2020

Aug 14, 2020

BUY
$2.67 - $7.91 $58,953 - $174,652
22,080 New
22,080 $163,000
Q1 2020

May 15, 2020

SELL
$2.03 - $4.35 $77,318 - $165,682
-38,088 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$2.08 - $5.06 $48,986 - $119,168
23,551 Added 162.01%
38,088 $158,000
Q3 2018

Nov 13, 2018

BUY
$5.6 - $11.0 $81,407 - $159,907
14,537 New
14,537 $0

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $54.2M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.